EP0257956B2
(de)
|
1986-08-19 |
2000-11-22 |
Genentech, Inc. |
Verwendung von Polypeptidwuchsstoffen und Zytokinen zur Herstellung eines Geräts und einer Dispersion
|
US5766897A
(en)
*
|
1990-06-21 |
1998-06-16 |
Incyte Pharmaceuticals, Inc. |
Cysteine-pegylated proteins
|
US6582728B1
(en)
|
1992-07-08 |
2003-06-24 |
Inhale Therapeutic Systems, Inc. |
Spray drying of macromolecules to produce inhaleable dry powders
|
US5661125A
(en)
*
|
1992-08-06 |
1997-08-26 |
Amgen, Inc. |
Stable and preserved erythropoietin compositions
|
US6012450A
(en)
*
|
1993-01-29 |
2000-01-11 |
Aradigm Corporation |
Intrapulmonary delivery of hematopoietic drug
|
ES2218543T3
(es)
|
1994-03-07 |
2004-11-16 |
Nektar Therapeutics |
Procedimiento y preparacion para la administracion de insulina por via pulmonar.
|
US6051256A
(en)
|
1994-03-07 |
2000-04-18 |
Inhale Therapeutic Systems |
Dispersible macromolecule compositions and methods for their preparation and use
|
AU696387B2
(en)
|
1994-05-18 |
1998-09-10 |
Inhale Therapeutic Systems, Inc. |
Methods and compositions for the dry powder formulation of interferons
|
US6586006B2
(en)
|
1994-08-04 |
2003-07-01 |
Elan Drug Delivery Limited |
Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
|
US6290991B1
(en)
|
1994-12-02 |
2001-09-18 |
Quandrant Holdings Cambridge Limited |
Solid dose delivery vehicle and methods of making same
|
IL116085A
(en)
*
|
1994-12-16 |
1999-12-31 |
Ortho Pharma Corp |
Spray dried erythropoietin
|
US6485726B1
(en)
*
|
1995-01-17 |
2002-11-26 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of therapeutics
|
CA2216443A1
(en)
|
1995-03-31 |
1996-10-03 |
Aradigm Corporation |
Intrapulmonary delivery of hematopoietic drug
|
AU706195B2
(en)
*
|
1995-04-14 |
1999-06-10 |
Inhale Therapeutic Systems |
Powdered pharmaceutical formulations having improved dispersibility
|
US5869451A
(en)
|
1995-06-07 |
1999-02-09 |
Glaxo Group Limited |
Peptides and compounds that bind to a receptor
|
EP1961760A3
(de)
|
1995-06-07 |
2008-09-03 |
Glaxo Group Limited |
Peptide und Verbindungen, die einen Thrombopoietin-Rezeptor binden
|
DE19539574A1
(de)
*
|
1995-10-25 |
1997-04-30 |
Boehringer Mannheim Gmbh |
Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren
|
US5875776A
(en)
*
|
1996-04-09 |
1999-03-02 |
Vivorx Pharmaceuticals, Inc. |
Dry powder inhaler
|
CA2252814A1
(en)
*
|
1996-04-29 |
1997-11-06 |
Dura Pharmaceuticals, Inc. |
Methods of dry powder inhalation
|
US7091311B2
(en)
|
1996-06-07 |
2006-08-15 |
Smithkline Beecham Corporation |
Peptides and compounds that bind to a receptor
|
GB9612297D0
(en)
*
|
1996-06-11 |
1996-08-14 |
Minnesota Mining & Mfg |
Medicinal aerosol formulations
|
US5952226A
(en)
*
|
1996-11-05 |
1999-09-14 |
Modex Therapeutiques |
Hypoxia responsive EPO producing cells
|
US20030203036A1
(en)
|
2000-03-17 |
2003-10-30 |
Gordon Marc S. |
Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
|
GB9703673D0
(en)
*
|
1997-02-21 |
1997-04-09 |
Bradford Particle Design Ltd |
Method and apparatus for the formation of particles
|
DE19733651A1
(de)
*
|
1997-08-04 |
1999-02-18 |
Boehringer Ingelheim Pharma |
Wässrige Aerosolzubereitungen enthaltend biologisch aktive Markomoleküle und Verfahren zur Erzeugung entsprechender Aerosole
|
US20060165606A1
(en)
|
1997-09-29 |
2006-07-27 |
Nektar Therapeutics |
Pulmonary delivery particles comprising water insoluble or crystalline active agents
|
US6946117B1
(en)
|
1997-09-29 |
2005-09-20 |
Nektar Therapeutics |
Stabilized preparations for use in nebulizers
|
ATE239447T1
(de)
†
|
1997-09-29 |
2003-05-15 |
Inhale Therapeutic Syst |
In verneblern verwendbare, stabilisierte zubereitungen
|
US6565885B1
(en)
|
1997-09-29 |
2003-05-20 |
Inhale Therapeutic Systems, Inc. |
Methods of spray drying pharmaceutical compositions
|
WO1999054486A1
(en)
*
|
1998-04-22 |
1999-10-28 |
Cornell Research Foundation, Inc. |
Canine erythropoietin gene and recombinant protein
|
US6696411B1
(en)
|
1998-04-22 |
2004-02-24 |
Cornell Research Foundation, Inc. |
Canine erythropoietin gene and recombinant protein
|
MXPA01011429A
(es)
*
|
1999-05-11 |
2003-09-10 |
Ortho Mcneil Pharm Inc |
Modelado farmacocinetico y farmacodinamico de administracion de eritropoyetina.
|
US7332275B2
(en)
|
1999-10-13 |
2008-02-19 |
Sequenom, Inc. |
Methods for detecting methylated nucleotides
|
WO2001036604A2
(en)
|
1999-11-18 |
2001-05-25 |
Corvas International, Inc. |
Nucleic acids encoding endotheliases, endotheliases and uses thereof
|
SK11142002A3
(sk)
*
|
1999-12-30 |
2004-09-08 |
Chiron Corporation |
Liečivo na podávanie interleukínu-2 a stabilizovaný lyofilizovaný alebo sprejovo sušený farmaceutický prostriedok s obsahom interleukínu-2
|
US7700341B2
(en)
|
2000-02-03 |
2010-04-20 |
Dendreon Corporation |
Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
|
US8404217B2
(en)
|
2000-05-10 |
2013-03-26 |
Novartis Ag |
Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
|
MXPA02001323A
(es)
|
2000-05-10 |
2004-07-16 |
Alliance Pharma |
Microgranulos con base fosfolipida para la liberacion de farmaco.
|
US7871598B1
(en)
|
2000-05-10 |
2011-01-18 |
Novartis Ag |
Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
|
WO2001087329A1
(en)
*
|
2000-05-15 |
2001-11-22 |
F. Hoffmann-La Roche Ag |
Liquid pharmaceutical composition containing an erythropoietin derivate
|
US7575761B2
(en)
|
2000-06-30 |
2009-08-18 |
Novartis Pharma Ag |
Spray drying process control of drying kinetics
|
GB0027357D0
(en)
|
2000-11-09 |
2000-12-27 |
Bradford Particle Design Plc |
Particle formation methods and their products
|
CA2430318C
(en)
*
|
2000-11-29 |
2009-10-27 |
Itoham Foods Inc. |
Powder formulation and method for producing the same
|
US20030072737A1
(en)
*
|
2000-12-29 |
2003-04-17 |
Michael Brines |
Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
|
US7767643B2
(en)
|
2000-12-29 |
2010-08-03 |
The Kenneth S. Warren Institute, Inc. |
Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
|
ES2284858T3
(es)
*
|
2001-02-02 |
2007-11-16 |
Ortho-Mcneil Pharmaceutical, Inc. |
Tratamiento de disfuncion neurologica que comprende sulfamatos de fructopiranosa y eritropoyetina.
|
US20030072717A1
(en)
*
|
2001-02-23 |
2003-04-17 |
Vapotronics, Inc. |
Inhalation device having an optimized air flow path
|
AU2002305052A1
(en)
|
2001-03-13 |
2002-09-24 |
Corvas International, Inc. |
Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
|
GB0107106D0
(en)
*
|
2001-03-21 |
2001-05-09 |
Boehringer Ingelheim Pharma |
Powder inhaler formulations
|
JP2004535166A
(ja)
|
2001-03-22 |
2004-11-25 |
デンドレオン・サンディエゴ・リミテッド・ライアビリティ・カンパニー |
セリンプロテアーゼcvsp14をコードする核酸分子、コードされるポリペプチドおよびそれに基づく方法
|
AU2002310054B2
(en)
*
|
2001-05-21 |
2007-02-01 |
Injet Digital Aerosols Limited |
Compositions for protein delivery via the pulmonary route
|
EG24184A
(en)
|
2001-06-15 |
2008-10-08 |
Otsuka Pharma Co Ltd |
Dry powder inhalation system for transpulmonary
|
GB0208742D0
(en)
|
2002-04-17 |
2002-05-29 |
Bradford Particle Design Ltd |
Particulate materials
|
ATE508735T1
(de)
|
2001-12-19 |
2011-05-15 |
Novartis Ag |
Pulmonale verabreichung von aminoglykosiden
|
WO2003055526A2
(en)
*
|
2001-12-21 |
2003-07-10 |
Maxygen Aps |
Erythropoietin conjugates
|
US7582284B2
(en)
|
2002-04-17 |
2009-09-01 |
Nektar Therapeutics |
Particulate materials
|
GB0216562D0
(en)
|
2002-04-25 |
2002-08-28 |
Bradford Particle Design Ltd |
Particulate materials
|
CA2484676A1
(en)
|
2002-05-03 |
2003-11-13 |
Sequenom, Inc. |
Kinase anchor protein muteins, peptides thereof, and related methods
|
US9339459B2
(en)
|
2003-04-24 |
2016-05-17 |
Nektar Therapeutics |
Particulate materials
|
US20040009908A1
(en)
*
|
2002-07-10 |
2004-01-15 |
Stamler Jonathan S. |
Methods for treating or preventing ischemic injury
|
DE10234192B4
(de)
|
2002-07-26 |
2009-11-26 |
Epoplus Gmbh Co.Kg |
Verwendung von Erythropoetin
|
DE10234165B4
(de)
*
|
2002-07-26 |
2008-01-03 |
Advanced Micro Devices, Inc., Sunnyvale |
Verfahren zum Füllen eines Grabens, der in einem Substrat gebildet ist, mit einem isolierenden Material
|
PT1542714E
(pt)
|
2002-09-18 |
2014-06-23 |
Janssen Pharmaceuticals Inc |
Métodos para aumentar a produção de células estaminais plaquetárias e hematopoiéticas
|
EP1852441B1
(de)
|
2002-09-24 |
2012-03-28 |
The Burnham Institute |
Mittel zur Modulierung der EPH-Rezeptor-Aktivität
|
US7923032B2
(en)
*
|
2002-11-26 |
2011-04-12 |
Seacoast Neuroscience, Inc. |
Buoyant polymer particles for delivery of therapeutic agents to the central nervous system
|
US20040132645A1
(en)
*
|
2003-01-03 |
2004-07-08 |
Knox Susan J. |
Methods for modulating effects of radiation in a subject
|
EP2397128A1
(de)
|
2003-02-14 |
2011-12-21 |
Children's Hospital & Research Center at Oakland |
Verwendung von L-Arginine und ggf. Magnesium zur Behandlung von Sichelzellenanämie und/oder pulmonaler Hypertonie
|
WO2004091495A2
(en)
*
|
2003-04-09 |
2004-10-28 |
University Of Utah Research Foundation |
Compositions and methods related to production of erythropoietin
|
DE102004004509B4
(de)
*
|
2004-01-23 |
2010-07-01 |
Epoplus Gmbh Co.Kg |
Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden
|
EP1848461A2
(de)
*
|
2005-02-16 |
2007-10-31 |
Nektar Therapeutics Al, Corporation |
Konjugate einer epo-gruppierung und eines polymers
|
US7974856B2
(en)
|
2005-11-30 |
2011-07-05 |
The Invention Science Fund I, Llc |
Computational systems and methods related to nutraceuticals
|
US8068991B2
(en)
|
2005-11-30 |
2011-11-29 |
The Invention Science Fund I, Llc |
Systems and methods for transmitting pathogen related information and responding
|
US8000981B2
(en)
|
2005-11-30 |
2011-08-16 |
The Invention Science Fund I, Llc |
Methods and systems related to receiving nutraceutical associated information
|
US7927787B2
(en)
|
2006-06-28 |
2011-04-19 |
The Invention Science Fund I, Llc |
Methods and systems for analysis of nutraceutical associated components
|
US8297028B2
(en)
|
2006-06-14 |
2012-10-30 |
The Invention Science Fund I, Llc |
Individualized pharmaceutical selection and packaging
|
US7827042B2
(en)
|
2005-11-30 |
2010-11-02 |
The Invention Science Fund I, Inc |
Methods and systems related to transmission of nutraceutical associated information
|
US10296720B2
(en)
|
2005-11-30 |
2019-05-21 |
Gearbox Llc |
Computational systems and methods related to nutraceuticals
|
US8340944B2
(en)
|
2005-11-30 |
2012-12-25 |
The Invention Science Fund I, Llc |
Computational and/or control systems and methods related to nutraceutical agent selection and dosing
|
TW200810773A
(en)
*
|
2006-04-19 |
2008-03-01 |
Alba Therapeutics Corp |
Use of tight junction agonists to facilitate the pulmonary delivery of therapeutic agents
|
KR101778174B1
(ko)
|
2006-07-05 |
2017-09-13 |
카탈리스트 바이오사이언시즈, 인코포레이티드 |
프로테아제 스크리닝 방법 및 이에 의해 확인된 프로테아제
|
MX2009008582A
(es)
|
2007-02-11 |
2009-10-30 |
Map Pharmaceuticals Inc |
Metodo para la administracion terapeutica de dihidroergotamina para permitir un rapido alivio de la migraña mientras se minimiza el perfil de efectos secundarios.
|
HRP20230761T1
(hr)
|
2008-08-14 |
2023-10-13 |
Acceleron Pharma Inc. |
Gdf zamke
|
MX350838B
(es)
|
2011-02-11 |
2017-09-18 |
Grain Proc Corporation * |
Composicion de sal.
|
CA2852683A1
(en)
*
|
2011-10-17 |
2013-04-25 |
Acceleron Pharma, Inc. |
Methods and compositions for treating ineffective erythropoiesis
|
EP3272769B1
(de)
|
2012-01-26 |
2020-06-17 |
Christopher J. Soares |
Peptidantagonisten aus der calcitonin-cgrp-familie von peptidhormonen und deren verwendung
|
US20140350087A9
(en)
|
2012-03-22 |
2014-11-27 |
Halozyme, Inc. |
Oncovector Nucleic Acid Molecules and Methods of Use
|
US10105410B2
(en)
|
2014-03-10 |
2018-10-23 |
Rambam Med-Tech Ltd. |
Heparanase inhibitory peptides and use thereof for treating clinical pathologies
|
US20180050005A1
(en)
|
2016-08-16 |
2018-02-22 |
Janssen Pharmaceutica Nv |
Concentrated Solution of 17-Hydroxydocosahexaenoic Acid
|
ES2965087T3
(es)
|
2016-09-02 |
2024-04-10 |
Soares Christopher J |
Uso de antagonistas de receptor de CGRP en el tratamiento de glaucoma
|
EP3658191A1
(de)
|
2017-07-26 |
2020-06-03 |
Janssen Pharmaceutica NV |
Verfahren zum schutz der gefässintegrität durch gezielte strahlentherapie
|
MX2021008928A
(es)
|
2019-01-25 |
2021-11-04 |
Janssen Pharmaceutica Nv |
Métodos para mejorar la protección contra lesiones vasculares y de organos, la recuperación hematopoyética y la supervivencia en respuesta a la radiacion corporal total/exposicion química.
|
CA3127378A1
(en)
|
2019-01-25 |
2020-10-15 |
Janssen Pharmaceutica Nv |
Methods of mitigating toxic effects of vesicants and caustic gas
|
AU2020211412A1
(en)
|
2019-01-25 |
2021-08-12 |
Janssen Pharmaceutica Nv |
Methods for mitigating liver injury and promoting liver hypertrophy, regeneration and cell engraftment in conjunction with radiation and/or radiomimetic treatments
|
EP3946417A1
(de)
|
2019-03-29 |
2022-02-09 |
Pieris Pharmaceuticals GmbH |
Inhalierte verabreichung von lipocalin-muteinen
|
EP4007597A2
(de)
|
2019-08-01 |
2022-06-08 |
ACM Biolabs Pte Ltd |
Verfahren zur auslösung einer immunreaktion durch verabreichung einer population von polymersomen mit einem assoziierten antigen zusammen mit einer population von polymersomen mit einem assoziierten adjuvans sowie zusammensetzungen mit den zwei populationen von polymersomen
|
AU2021260857A1
(en)
|
2020-04-24 |
2022-11-03 |
Acm Biolabs Pte Ltd |
Vaccine against human-pathogenic coronaviruses
|
AU2021396659A1
(en)
|
2020-12-11 |
2023-05-04 |
Acm Biolabs Pte Ltd |
Modulating th1/th2 immune response by administering two populations of polymersomes having an associated antigen and an associated adjuvant
|
CA3204785A1
(en)
|
2021-02-02 |
2022-08-11 |
Madhavan Nallani |
Sole use of polymersome associated adjuvant for stimulating an immune response
|
AU2022253567A1
(en)
|
2021-04-08 |
2023-11-23 |
Pieris Pharmaceuticals Gmbh |
Novel lipocalin muteins specific for connective tissue growth factor (ctgf)
|
WO2023056444A1
(en)
|
2021-10-01 |
2023-04-06 |
Janssen Pharmaceutica N.V. |
Methods of increasing progenitor cell production
|
WO2023168426A1
(en)
|
2022-03-03 |
2023-09-07 |
Enosi Therapeutics Corporation |
Compositions and cells containing mixtures of oligo-trap fusion proteins (ofps) and uses thereof
|